 |
|
Treatment for Chronic Fatigue Syndrome
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Peterson et al1 propose a number of factors that could explain the different outcomes in their trial and those of Bou-Holaigah et al,2 who found fludrocortisone acetate to benefit patients with chronic fatigue syndrome. However, Peterson et al fail to mention an additional factor that should not be overlooked, namely, the different forms in which fludrocortisone was administered. Bou-Holaigah et al gave their patients the drug in the form of tablets, whereas Peterson et al gave their subjects tablets hidden in capsules. This masking may have biased their results. In fact, the dissolution times of tablets extemporaneously converted to capsules are strikingly prolonged.3 Therefore, it is appropriate to point out that "[s]lowing down the dissolution rate of a commercial drug used as a control in a clinical trial could severely bias the results of such trials."3
Fludrocortisone acetate has such powerful water-retaining effects that a daily dose of 0.1 mg . . . [Full Text of this Article]
RELATED LETTER
Chronic Fatigue Syndrome, Decreased Exercise Capacity, and Adrenal Insufficiency
Riccardo Baschetti, Pascale De Becker, and Kenny De Meirleir
Arch Intern Med. 2001;161(12):1558-1559.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Chronic Fatigue Syndrome, Decreased Exercise Capacity, and Adrenal Insufficiency
Baschetti et al.
Arch Intern Med 2001;161:1558-1559.
FULL TEXT
Orthostatic Hypotension and Chronic Fatigue Syndrome
Baschetti et al.
JAMA 2001;285:1441-1443.
FULL TEXT
Low-Dose Hydrocortisone for Chronic Fatigue Syndrome
Baschetti et al.
JAMA 1999;281:1887-1889.
FULL TEXT
|
